Exact Sciences Corporation (EXAS)

業務介紹

Exact Sciences Corporation（Exact Sciences 公司）在美國和國際市場提供癌症篩查和診斷測試產品。該公司提供Cologuard，一種非侵入性的基於大便DNA的篩查測試，用於檢測與結腸直腸癌和癌前病變相關的DNA和血紅蛋白生物標記。它還提供Oncotype DX，一種基因表達測試，用於乳腺癌、前列腺癌和結腸癌；Oncotype Test，一種組織測試，提供腫瘤分析，幫助選擇對於晚期、轉移性、難治性或復發性癌症患者的治療方案；Oncotype DX AR-V7 Nucleus Detect Test，一種液體測試，用於晚期前列腺癌；Oncomap ExTra，提供某些難治性、罕見或侵略性癌症的完整生物學圖像；以及Covid-19測試服務。該公司的產品開發項目主要集中在提高Cologuard測試的性能特點以及開發基於血液和其他體液的測試上。它與MAYO Foundation for Medical Education and Research和Hologic, Inc.簽訂了許可協議。Exact Sciences Corporation成立於1995年，總部位於威斯康辛州麥迪遜市。

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

公司網址

https://www.exactsciences.com